USPTO Examiner PERREIRA MELISSA JEAN - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18927047Stable, concentrated radionuclide complex solutionsOctober 2024May 2025Allow701YesNo
18927034Stable, concentrated radionuclide complex solutionsOctober 2024February 2025Abandon400NoNo
18640884Stable, concentrated radionuclide complex solutionsApril 2024September 2024Allow500YesNo
18640917Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640907Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18640891Stable, concentrated radionuclide complex solutionsApril 2024October 2024Allow600YesNo
18612564LIPIDS AND COMPOSITIONS THEREOFMarch 2024January 2025Allow1010YesNo
18585905IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)February 2024August 2024Allow600NoNo
18410875Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use ThereofJanuary 2024October 2024Abandon910NoNo
18572198PREPARATION METHOD OF NANOZYME COMPOSITE-BASED HYBRID HYDROGEL EYE DROPDecember 2023July 2024Allow600NoNo
18526168Method to Improve the Encapsulation Efficiency and Physicochemical Stability of Ginsenosides Rg3 and CK Nano-emulsionDecember 2023July 2024Allow710NoNo
18565770MANUFACTURING OF DIMERIC CONTRAST AGENTSNovember 2023March 2025Allow1630YesNo
18512708RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERSNovember 2023November 2024Allow1221NoNo
18474209FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOFSeptember 2023April 2025Allow1920NoNo
18546989DUAL-TARGETING COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOFAugust 2023March 2024Allow710NoNo
18448609METHOD OF TREATING PROSTATE CANCERAugust 2023June 2025Abandon2340YesNo
18354282IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)July 2023January 2024Allow610YesNo
18257063TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOFJune 2023January 2024Allow710NoNo
18189238MULTI-SIGNAL FLUORESCENT PROBE FOR EARLY DIAGNOSIS OF TUMORS, AND PREPARATION AND USE THEREOFMarch 2023June 2023Allow300NoNo
18111704COMPOSITIONS INCLUDING PAFOLACIANINE FOR THE IDENTIFICATION OF MALIGNANT LESIONSFebruary 2023January 2024Allow1120YesNo
17907973NEAR-INFRARED FLUORESCENT PROBE SPECIFICALLY TARGETING TUMORS AS WELL AS SYNTHESIS METHOD AND USE THEREOFAugust 2022May 2025Allow3320NoNo
17884185Unassisted Robotic Surgery Employing Paramagnetic Halo Metallofullerenes as Minimally Invasive, Precision Scalpels or Micronization Particles through Magnetic Field Manipulation and Targeted Exenteration Patterned by Programmed 3D Imaging Using Needle or Magnetic Energy Access and Microelectronic Semiconducting in Non-stationary Wafer-less Space.August 2022March 2023Allow721YesNo
17867030METHODS OF FUNCTIONALIZING NANOPARTICLESJuly 2022January 2025Abandon3050NoNo
17718812PSMA-TARGETING COMPOUNDS AND USES THEREOFApril 2022September 2022Allow510NoNo
17767039SYSTEMS AND METHODS OF ISOLATION OF GALLIUM-68April 2022September 2023Abandon1710NoNo
17697401RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASE DIAGNOSIS AND THERAPYMarch 2022February 2023Abandon1111NoNo
17697416SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASESMarch 2022September 2022Allow601NoNo
17633843METHOD AND REAGENTS FOR DETECTING LUCIFERASE ACTIVITYFebruary 2022April 2024Abandon2611NoNo
17461860RADIOPHARMACEUTICAL AND METHODSAugust 2021August 2022Allow1110YesNo
17397022COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED OF A DIASTEREOISOMERICALLY ENRICHED PCTA AND SYNTHESIS METHODAugust 2021June 2022Allow1020YesNo
17423589COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED OF A DIASTEREOISOMERICALLY ENRICHED PCTA AND SYNTHESIS METHODJuly 2021May 2025Abandon4610NoNo
17374984RADIOPHARMACEUTICAL AND METHODSJuly 2021September 2022Allow1420YesNo
17373987SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOFJuly 2021March 2025Allow4410NoNo
17371663NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOFJuly 2021February 2025Abandon4410NoNo
17371587RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGENJuly 2021August 2022Allow1430YesNo
17369104MODIFIED NANODELIVERY SYSTEM AND METHOD FOR ENHANCED IN VIVO MEDICAL AND PRECLINICAL IMAGINGJuly 2021August 2024Allow3700NoNo
17359490COMPOSITIONS AND METHODS FOR DETECTING ACE2 EXPRESSION PROFILESJune 2021December 2023Abandon2910NoNo
17355286SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOFJune 2021November 2024Allow4110NoNo
17331927Methods for Synthesis of Radionuclide ComplexMay 2021February 2025Abandon4420NoNo
17331113PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERYMay 2021April 2024Allow3410NoNo
17318802Organic Anion Transporting Peptide-Based Cancer Imaging and TherapyMay 2021April 2025Allow4720NoNo
17233102MECHANICAL OPENING OF LIPID BILAYERS BY MOLECULAR NANOMACHINESApril 2021September 2022Allow1740YesNo
17209121Stable, concentrated radionuclide complex solutionsMarch 2021December 2023Abandon3210NoNo
17209122Stable, concentrated radionuclide complex solutionsMarch 2021November 2023Abandon3210NoNo
17204196ENHANCED SURGICAL VISUALIZATION OF VIABLE TISSUE AND PEPTIDES THEREFORMarch 2021November 2024Abandon4410NoNo
17199122GADOLINIUM BEARING PCTA-BASED CONTRAST AGENTSMarch 2021March 2024Allow3610YesNo
17185502Compounds and Methods of Making CompoundsFebruary 2021February 2024Abandon3610NoNo
17127754ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USEDecember 2020June 2024Allow4130YesNo
17117424PHYSIOLOGICALLY STABLE FLUOROPHORE AND PERFORMING FLUORESCENCE PROBINGDecember 2020November 2023Allow3520YesNo
17116596BISMUTH-IRON OXIDE CONTRAST AGENTSDecember 2020May 2024Abandon4120NoNo
16973254Pretreatment Method for Fluorescent Image DiagnosisDecember 2020April 2025Allow5230YesNo
17114195SYNTHESIS AND COMPOSITION OF NON-AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORSDecember 2020April 2024Allow4010NoNo
17112075Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen LigandsDecember 2020August 2023Allow3210NoNo
17112497PSMA-TARGETED NIR DYES AND THEIR USESDecember 2020October 2024Abandon4730NoNo
17105308SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORSNovember 2020July 2024Allow4420YesNo
17057284ONE-STEP, FAST, 18F-19F ISOTOPIC EXCHANGE RADIOLABELING OF DIFLUORO-DIOXABORININS AND USE OF SUCH COMPOUNDS IN TREATMENTNovember 2020March 2025Allow5221YesNo
17057506RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPYNovember 2020March 2024Allow4020NoNo
16950107HNQO1-ACTIVATABLE FLUORESCENT PROBE FOR IMAGING CANCER CELLS IN-VITRO AND IN-VIVONovember 2020December 2023Allow3710NoNo
17092587ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USENovember 2020January 2023Allow2610NoNo
17093184SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOFNovember 2020August 2023Allow3320NoNo
17050370NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRASTOctober 2020October 2024Abandon4720NoNo
17074832RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEREOFOctober 2020July 2023Abandon3301NoNo
17047748CYCLOPHANES FOR LIVE-CELL IMAGINGOctober 2020June 2023Allow3210NoNo
17046053TARGETING COMPOUNDS AND METHODS FOR THEIR PRODUCTIONOctober 2020December 2023Allow3830NoNo
17060396DIMERIC CONTRAST AGENTSOctober 2020June 2022Allow2010YesNo
17042534USE OF BIS-IMINOBIOTIN COMPOUND FOR DRUG DELIVERY PURPOSESSeptember 2020June 2023Abandon3310NoNo
17042772FORMULATIONS AND KITS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGINGSeptember 2020March 2023Allow3030NoNo
17029226PSMA-TARGETED NIR DYES AND THEIR USESSeptember 2020June 2022Allow2110NoNo
17025711CA IX - NIR DYES AND THEIR USESSeptember 2020September 2022Allow2410NoNo
16980252177Lu-DOTA-HYNIC-iPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGENSeptember 2020August 2024Allow4760YesNo
16971671POSITRON EMISSION TOMOGRAPHY IMAGING OF ACTIVATABLE BINDING POLYPEPTIDES AND RELATED COMPOSITIONS THEREOFAugust 2020June 2025Abandon5720NoYes
16970155HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMSAugust 2020June 2023Allow3420NoNo
16990368MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGINGAugust 2020April 2022Allow2010NoNo
16967624COMPOUND FOR INTRAOPERATIVE MOLECULAR BIOIMAGING, METHOD OF MAKING THE SAME, USE THEREOF IN INTRAOPERATIVE MOLECULAR BIOIMAGING AND SURGICAL METHOD COMPRISING INTRAOPERATIVE MOLECULAR BIOIMAGINGAugust 2020June 2024Abandon4720NoNo
16966182BIOINK COMPOSITION FOR DERMIS REGENERATION SHEET, METHOD FOR MANUFACTURING CUSTOMIZED DERMIS REGENERATION SHEET USING SAME, AND CUSTOMIZED DERMIS REGENERATION SHEET MANUFACTURED USING MANUFACTURING METHODJuly 2020February 2024Abandon4211YesNo
16926807TARGETED PHOTOACOUSTIC AGENTS AND USES THEREOFJuly 2020October 2023Abandon3920NoNo
16919562Methods of Using C-Met ModulatorsJuly 2020April 2022Allow2210NoNo
16905702ASSESSMENT OF IRON DEPOSITION POST MYOCARDIAL INFARCTION AS A MARKER OF MYOCARDIAL HEMORRHAGEJune 2020February 2023Allow3210NoNo
16905718ASSESSMENT OF IRON DEPOSITION POST MYOCARDIAL INFARCTION AS A MARKER OF MYOCARDIAL HEMORRHAGEJune 2020February 2023Allow3210NoNo
16771061ANTICANCER FLUORESCENT SUBSTANCE DERIVED FROM NATURAL MATERIALSJune 2020July 2023Abandon3730NoNo
16895263COMPRESSED SOLID COMPOSITION FOR MRIJune 2020December 2020Allow611YesNo
16894794METHOD AND DEVICE FOR PRODUCING OPTIMIZED LIPID-BASED MICRO/NANO-BUBBLESJune 2020March 2022Abandon2111NoNo
16893330CROSSLINKED HYDROGEL COMPOSITIONS FOR REGULATING STATES OF ENCAPSULATED CANCER CELLSJune 2020April 2024Allow4721YesNo
16892060TREATMENT OF METAHNOGENIC BACTERIA AS A THERAPY FOR CHRONIC LUNG DISEASEJune 2020March 2024Abandon4530YesNo
16891181Radioactive Phospholipid Metal Chelates for Cancer Imaging and TherapyJune 2020August 2021Allow1410NoNo
16887754METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPYMay 2020January 2022Abandon2010NoNo
16888114METHODS FOR PRESERVING A SUBJECT AND USING IMAGING CONTRAST AGENTSMay 2020September 2023Allow4040YesNo
16766619GADOLINIUM BEARING PCTA-BASED CONTRAST AGENTSMay 2020February 2021Allow810YesNo
16879851DYE-PROTEIN COMPLEX FOR NIR II AND PHOTOACOUSTIC IMAGINGMay 2020February 2023Abandon3330YesNo
16765927A DOUBLE-LABELED PROBE FOR MOLECULAR IMAGING AND USE THEREOFMay 2020December 2022Allow3120NoNo
16765729PSMA ligands for imaging and endoradiotherapyMay 2020April 2022Allow2310NoNo
16876606SIZE-VARYING BUBBLE COMPLEX AND METHOD OF PREPARING THE SAMEMay 2020August 2022Allow2711NoNo
16848586MEROCYANINE-BASED COMPOUND AND BIOMOLECULAR LABELING DYE, KIT AND CONTRAST AGENT COMPOSITION COMPRISING SAMEApril 2020February 2022Allow2200NoNo
16754986SYSTEM AND METHOD TO CONTROL NUCLEATION OF BUBBLESApril 2020January 2023Allow3330YesNo
16831899SALINE NANODROPLETS FOR RADIO-FREQUENCY-ACOUSTIC MOLECULAR IMAGINGMarch 2020March 2022Abandon2410NoNo
16828119COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTSMarch 2020September 2022Abandon3020NoYes
16827606Stable, concentrated radionuclide complex solutionsMarch 2020January 2023Allow3420NoNo
16824139NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATIONMarch 2020April 2021Allow1300NoNo
16820052PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERYMarch 2020January 2021Allow1011YesNo
16816118Near-Infrared Dyes And Conjugates For Targeting TumorsMarch 2020April 2024Allow5040YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PERREIRA, MELISSA JEAN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
42
Examiner Affirmed
33
(78.6%)
Examiner Reversed
9
(21.4%)
Reversal Percentile
33.4%
Lower than average

What This Means

With a 21.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
135
Allowed After Appeal Filing
29
(21.5%)
Not Allowed After Appeal Filing
106
(78.5%)
Filing Benefit Percentile
25.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 21.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PERREIRA, MELISSA JEAN - Prosecution Strategy Guide

Executive Summary

Examiner PERREIRA, MELISSA JEAN works in Art Unit 1618 and has examined 912 patent applications in our dataset. With an allowance rate of 50.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner PERREIRA, MELISSA JEAN's allowance rate of 50.1% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PERREIRA, MELISSA JEAN receive 2.51 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PERREIRA, MELISSA JEAN is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +27.2% benefit to allowance rate for applications examined by PERREIRA, MELISSA JEAN. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 13.9% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 35.9% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 57.6% of appeals filed. This is in the 26% percentile among all examiners. Of these withdrawals, 59.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 67.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.6% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.